Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
gut microbiota1104 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A22847 | 24274865 | Clin Liver Dis | Obesity and NAFLD: the role of bacteria and microbiota. | 2013 | Details |
| A22859 | 24251697 | J Gastroenterol Hepatol | Role of the gut microbiota in human nutrition and metabolism. | 2013 | Details |
| A22932 | 24196453 | Semin Immunopathol | Gut microbiome and metabolic diseases. | 2013 | Details |
| A22946 | 24187469 | World J Gastroenterol | Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. | 2013 | Details |
| A23020 | 24113768 | Am J Physiol Gastrointest Liver Physiol | Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model. | 2013 | Details |
| A23137 | 24010102 | Pediatr Gastroenterol Hepatol Nutr | Gut microbiota and clinical disease: obesity and nonalcoholic Fatty liver disease. | 2013 | Details |
| A23206 | 23959503 | Hepatology | Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. | 2014 | Details |
| A23208 | 23958600 | Nat Rev Gastroenterol Hepatol | The Gordian Knot of dysbiosis, obesity and NAFLD. | 2013 | Details |
| A23277 | 23905917 | J Allergy Clin Immunol | Innate sensors of pathogen and stress: linking inflammation to obesity. | 2013 | Details |
| A23300 | 23885277 | Hepat Mon | Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. | 2013 | Details |
| A23305 | 23880135 | Curr Opin Microbiol | Colonic bacterial metabolites and human health. | 2013 | Details |
| A23319 | 23873346 | Curr Opin Clin Nutr Metab Care | The gut-liver axis. | 2013 | Details |
| A23386 | 23827477 | Trends Endocrinol Metab | Non-alcoholic steatohepatitis: a microbiota-driven disease. | 2013 | Details |
| A23414 | 23803760 | Nature | Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. | 2013 | Details |
| A23719 | 23538296 | JPEN J Parenter Enteral Nutr | Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota? | 2013 | Details |
| A23810 | 23454028 | Clin Gastroenterol Hepatol | Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. | 2013 | Details |
| A23811 | 23453736 | Syst Appl Microbiol | Structural changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a Chinese herbal formula. | 2013 | Details |
| A23815 | 23452163 | Clin Microbiol Infect | Gut microbiota and non-alcoholic fatty liver disease: new insights. | 2013 | Details |
| A23895 | 23360884 | Br J Nutr | Gut microbiota and metabolic disorders: How prebiotic can work? | 2013 | Details |
| A24042 | 23287807 | J Pediatr Gastroenterol Nutr | Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. | 2013 | Details |
| A24049 | 23280158 | Dig Liver Dis | Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. | 2012 | Details |
| A24127 | 23203768 | Mol Nutr Food Res | Prebiotic approach alleviates hepatic steatosis: implication of fatty acid oxidative and cholesterol synthesis pathways. | 2012 | Details |
| A24132 | 23197411 | Gut | Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. | 2012 | Details |
| A24157 | 23174203 | Proc Nutr Soc | The gut microbial metabolome: modulation of cancer risk in obese individuals. | 2012 | Details |
| A24605 | 22700625 | Ann Hepatol |  Gut microbiota and nonalcoholic fatty liver disease. | 2012 | Details |
| A24712 | 22570745 | Gut Liver | NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. | 2012 | Details |
| A24739 | 22546554 | Nutr Metab Cardiovasc Dis | Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. | 2012 | Details |
| A24795 | 22482724 | Cell Metab | Is predisposition to NAFLD and obesity communicable? | 2012 | Details |
| A24968 | 22297845 | Nature | Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. | 2012 | Details |
| A25040 | 22221818 | Liver Int | The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. | 2011 | Details |
| A25278 | 22013810 | Zhongguo Zhong Xi Yi Jie He Za Zhi | [The key target of Chinese medicine treatment on alcoholic and nonalcoholic fatty liver disease: the gut]. | 2011 | Details |
| A25385 | 21901256 | Dig Dis Sci | Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. | 2011 | Details |
| A25508 | 21742296 | Clin Res Hepatol Gastroenterol | Liver fibrogenesis and metabolic factors. | 2011 | Details |
| A25939 | 21292470 | J Nutr Biochem | Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. | 2011 | Details |
| A26084 | 21129376 | Gastroenterology | Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. | 2010 | Details |
| A26131 | 21045794 | Nat Rev Gastroenterol Hepatol | The role of the gut microbiota in nonalcoholic fatty liver disease. | 2010 | Details |
| A26272 | 20804522 | Obes Rev | Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? | 2010 | Details |
| A26711 | 19915460 | Curr Opin Lipidol | Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. | 2010 | Details |
| A27960 | 16895997 | Proc Natl Acad Sci U S A | Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. | 2006 | Details |
| A29086 | 34603061 | Front Pharmacol | Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation. | 2021 | Details |
| A29173 | 34473374 | FASEB J | Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases. | 2021 | Details |
| A29742 | 33590776 | Gut Microbes | The contribution of gut bacterial metabolites in the human immune signaling pathway of non-communicable diseases. | 2022 | Details |
| A30168 | 32875214 | ACS Omega | Epigallocatechin Gallate Protects Mice against Methionine-Choline-Deficient-Diet-Induced Nonalcoholic Steatohepatitis by Improving Gut Microbiota To Attenuate Hepatic Injury and Regulate Metabolism. | 2020 | Details |
| A30489 | 32355675 | Hepatobiliary Surg Nutr | Probiotics VSL#3 are effective in reversing non-alcoholic steatohepatitis in a mouse model. | 2020 | Details |
| A30490 | 32355674 | Hepatobiliary Surg Nutr | Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease. | 2020 | Details |
| A31416 | 30618372 | Ugeskr Laeger | [The gut microbiome is important in chronic liver disease]. | 2019 | Details |
| A31619 | 30186272 | Front Microbiol | Butyrate Protects Mice Against Methionine-Choline-Deficient Diet-Induced Non-alcoholic Steatohepatitis by Improving Gut Barrier Function, Attenuating Inflammation and Reducing Endotoxin Levels. | 2018 | Details |
| A31765 | 29900399 | Data Brief | The effect of synbiotics Bifidobacterium infantis and milk oligosaccharides on shaping gut microbiota community structure and NASH treatment. | 2018 | Details |
| A31938 | 29515780 | Oncotarget | Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice. | 2018 | Details |
| A32521 | 28214071 | Trends Endocrinol Metab | Lipocalin-2: A Master Mediator of Intestinal and Metabolic Inflammation. | 2017 | Details |
| A32526 | 28202625 | Cancer Discov | Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE2-Mediated Suppression of Antitumor Immunity. | 2017 | Details |
| A33064 | 26758786 | Nat Rev Gastroenterol Hepatol | Immunology in the liver--from homeostasis to disease. | 2016 | Details |
| A34367 | 23638162 | PLoS One | Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study. | 2013 | Details |
| A42242 | 35118020 | J Lipid Atheroscler | Metabolism and Health Impacts of Dietary Sugars. | 2022 | Details |
| A42370 | 34741331 | Aliment Pharmacol Ther | Letter: cross-linkage between bacterial taxonomy and gene functions-a study of metagenome-assembled genomes of gut microbiota in adult non-alcoholic fatty liver disease. | 2021 | Details |
| A42386 | 34704503 | Crit Rev Food Sci Nutr | Effects and mechanisms of tea on obesity. | 2021 | Details |
| A42388 | 34698580 | Crit Rev Food Sci Nutr | Effect of kombucha intake on the gut microbiota and obesity-related comorbidities: A systematic review. | 2021 | Details |
| A42396 | 34674606 | Gut Microbes | Akkermansia muciniphila: is it the Holy Grail for ameliorating metabolic diseases? | 2022 | Details |
| A42402 | 34633856 | Annu Rev Nutr | Microbial Flavonoid Metabolism: A Cardiometabolic Disease Perspective. | 2021 | Details |
| A42412 | 34603218 | Front Endocrinol (Lausanne) | Editorial: The Brain - Gut - Microbiome Network in Metabolic Regulation and Dysregulation. | 2021 | Details |
| A42470 | 34449134 | Obesity (Silver Spring) | Salmon peptides limit obesity-associated metabolic disorders by modulating a gut-liver axis in vitamin D-deficient mice. | 2021 | Details |
| A42476 | 34439969 | Biology (Basel) | Aldehyde Dehydrogenase Mutation Exacerbated High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease with Gut Microbiota Remodeling in Male Mice. | 2021 | Details |
| A42477 | 34436472 | Metabolites | The Role of Gut Microbiota and Its Produced Metabolites in Obesity, Dyslipidemia, Adipocyte Dysfunction, and Its Interventions. | 2021 | Details |
| A42511 | 34328191 | Int J Mol Med | Dysbiosis and liver diseases (Review). | 2021 | Details |
| A42518 | 34305616 | Front Pharmacol | Multi-Pharmacology of Berberine in Atherosclerosis and Metabolic Diseases: Potential Contribution of Gut Microbiota. | 2021 | Details |
| A42519 | 34292103 | Crit Rev Food Sci Nutr | Prebiotic inulin as a treatment of obesity related nonalcoholic fatty liver disease through gut microbiota: a critical review. | 2021 | Details |
| A42538 | 34220702 | Front Endocrinol (Lausanne) | Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders? | 2021 | Details |
| A42593 | 34080232 | Immunol Cell Biol | Zone defence - the gut microbiota position macrophages for optimal liver protection. | 2021 | Details |
| A42638 | 33933727 | Clin Nutr | Gender and gut microbiota composition determine hepatic bile acid, metabolic and inflammatory response to a single fast-food meal in healthy adults. | 2021 | Details |
| A42678 | 33813071 | Clin Gastroenterol Hepatol | Interaction of Microbiome, Diet, and Hospitalizations Between Brazilian and American Patients With Cirrhosis. | 2021 | Details |
| A42736 | 33604315 | J Hepatocell Carcinoma | Mechanisms Underlying Hepatocellular Carcinoma Progression in Patients with Type 2 Diabetes. | 2021 | Details |
| A42755 | 33568795 | Nat Rev Gastroenterol Hepatol | The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. | 2021 | Details |
| A42768 | 33527946 | Food Funct | Uridine attenuates obesity, ameliorates hepatic lipid accumulation and modifies the gut microbiota composition in mice fed with a high-fat diet. | 2021 | Details |
| A42780 | 33497712 | Metabolism | Role of the gut microbiota in type 2 diabetes and related diseases. | 2021 | Details |
| A42890 | 33188417 | J Nutr | Minor Changes in the Composition and Function of the Gut Microbiota During a 12-Week Whole Grain Wheat or Refined Wheat Intervention Correlate with Liver Fat in Overweight and Obese Adults. | 2021 | Details |
| A42949 | 32988545 | Poult Sci | Research Note: Increase of bad bacteria and decrease of good bacteria in the gut of layers with vs. without hepatic steatosis. | 2020 | Details |
| A42964 | 32939550 | J Nutr | A Novel Combination of Fruits and Vegetables Prevents Diet-Induced Hepatic Steatosis and Metabolic Dysfunction in Mice. | 2020 | Details |
| A42980 | 32895142 | Nan Fang Yi Ke Da Xue Xue Bao | [Gut microbiota-an important contributor to liver diseases]. | 2020 | Details |
| A43034 | 32755308 | Am J Physiol Gastrointest Liver Physiol | Microbiota on biotics: probiotics, prebiotics, and synbiotics to optimize growth and metabolism. | 2020 | Details |
| A43035 | 32751062 | Int J Mol Sci | Consumption of Wild Rice (Zizania latifolia) Prevents Metabolic Associated Fatty Liver Disease through the Modulation of the Gut Microbiota in Mice Model. | 2020 | Details |
| A43043 | 32714511 | Int J Obes Suppl | From obesity through gut microbiota to cardiovascular diseases: a dangerous journey. | 2020 | Details |
| A43074 | 32624568 | Exp Mol Med | Exercise training modulates the gut microbiota profile and impairs inflammatory signaling pathways in obese children. | 2020 | Details |
| A43183 | 32355686 | Hepatobiliary Surg Nutr | Modulation of the gut microbiota represents a new management for non-alcoholic fatty liver disease. | 2020 | Details |
| A43214 | 32274349 | J Clin Transl Hepatol | Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease. | 2019 | Details |
| A43239 | 32212018 | Dig Dis Sci | Correction to: Omega‑3 Fatty Acids and Gut Microbiota: A Reciprocal Interaction in Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A43360 | 31909364 | J Obes Metab Syndr | Effect of Diet on the Gut Microbiota Associated with Obesity. | 2019 | Details |
| A43363 | 31903735 | Obesity (Silver Spring) | Adipose Tissue Macrophage Phenotypes and Characteristics: The Key to Insulin Resistance in Obesity and Metabolic Disorders. | 2020 | Details |
| A43445 | 31694274 | Cancers (Basel) | Carcinogenesis and Metastasis in Liver: Cell Physiological Basis. | 2019 | Details |
| A43463 | 31657225 | Am J Physiol Gastrointest Liver Physiol | Role of gut microbiota in liver disease. | 2019 | Details |
| A43500 | 31576746 | Chem Res Toxicol | Dose-Dependent Effects of Triclocarban Exposure on Lipid Homeostasis in Rats. | 2019 | Details |
| A43568 | 31388093 | Nat Rev Immunol | The intestinal microbiota fuelling metabolic inflammation. | 2019 | Details |
| A43587 | 31345023 | J Agric Food Chem | Processed Meat Protein Promoted Inflammation and Hepatic Lipogenesis by Upregulating Nrf2/Keap1 Signaling Pathway in Glrx-Deficient Mice. | 2019 | Details |
| A43829 | 30767680 | Am J Physiol Gastrointest Liver Physiol | Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either. | 2019 | Details |
| A43873 | 30629464 | FASEB J | Maternal prebiotic supplementation reduces fatty liver development in offspring through altered microbial and metabolomic profiles in rats. | 2019 | Details |
| A43891 | 30553904 | JACC Heart Fail | Heart Failure and Liver Disease: Cardiohepatic Interactions. | 2018 | Details |
| A43895 | 30522511 | Lipids Health Dis | Cordycepin reduces weight through regulating gut microbiota in high-fat diet-induced obese rats. | 2018 | Details |
| A43896 | 30541093 | Am J Clin Nutr | A 12-wk whole-grain wheat intervention protects against hepatic fat: the Graandioos study, a randomized trial in overweight subjects. | 2018 | Details |
| A43919 | 30464044 | Gut | Gut microbiota dynamics and uraemic toxins: one size does not fit all. | 2018 | Details |
| A43990 | 30210263 | Mediators Inflamm | Response to: Comment on "Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease". | 2018 | Details |
| A43998 | 30185915 | Nat Rev Gastroenterol Hepatol | Inflammasomes in the gastrointestinal tract: infection, cancer and gut microbiota homeostasis. | 2018 | Details |